Lastly, a phase IIa study is investigating the combination with cyclin-dependent kinase 4/6 inhibitor palbociclib and fulvestrant in advanced HER2-positive/HR-positive BC patients (NCT04224272). The gene discussed is ERBB2; the disease is breast cancer.